"Fluorescein Angiography" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Visualization of a vascular system after intravenous injection of a fluorescein solution. The images may be photographed or televised. It is used especially in studying the retinal and uveal vasculature.
| Descriptor ID |
D005451
|
| MeSH Number(s) |
E01.370.370.050.350 E01.370.380.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluorescein Angiography".
Below are MeSH descriptors whose meaning is more specific than "Fluorescein Angiography".
This graph shows the total number of publications written about "Fluorescein Angiography" by people in this website by year, and whether "Fluorescein Angiography" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 5 | 5 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 3 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 3 | 3 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 4 | 4 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorescein Angiography" by people in Profiles.
-
Case series: The role of retinal ischemia in the pathogenesis and clinical manifestation of diabetic retinopathy. Optom Vis Sci. 2026 Aug; 103(8):e70090.
-
THE "SCOLEX" SIGN: A Distinct Hyperreflective Foci on the Wall of Serous Pigment Epithelial Detachments in Central Serous Chorioretinopathy - Micron Report Number Seven. Retina. 2026 May 01; 46(5):871-880.
-
Case series: The value of fundus autofluorescence in inherited macular disease. Optom Vis Sci. 2026 Mar; 103(3):e70036.
-
Clinical Characteristics and Outcomes in Central Serous Chorioretinopathy With Subretinal Hyper-Reflective Material: MICRoN Report 6. Am J Ophthalmol. 2026 Jun; 286:152-162.
-
Choroidal imaging biomarkers as predictors of recurrent central serous chorioretinopathy: A multicenter retrospective study - MICRoN report number five. Graefes Arch Clin Exp Ophthalmol. 2026 Jun; 264(6):1639-1647.
-
MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Ophthalmologica. 2026; 249(3):265-274.
-
Logistical, Ethical, and Technical Considerations in the World's First Face and Whole Eye Transplantation. Plast Reconstr Surg. 2026 08 01; 158(2):302e-310e.
-
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. Ophthalmology. 2026 04; 133(4):451-465.
-
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. Ophthalmology. 2026 May; 133(5):577-588.
-
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study. Graefes Arch Clin Exp Ophthalmol. 2026 Feb; 264(2):407-416.